Ocena postępowania diagnostycznego i terapeutycznego w ...

120. Murphy SB, Classification, staging and end results of treatment of childhood non-Hodgkin
lymphomas; dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7: 332-39.
121. Pituch-Noworolska A, Mazur B. Immunofenotypowa diagnostyka chłoniaków nieziarniczych
u dzieci. Post Biol Kom. 2008; 35: 103-12.
122. Spachacz R, Łabędzka A, Łabędzka-Gardy M. i wsp. Znaczenie badań cytogenetycznych w
diagnostyce chłoniaków nieziarniczych u dzieci. Now Lek. 2003; 72: 433-37.
123. van Krieken JH, Langerak AW, Macintyre EA i wsp. Improved reliability of lymphoma
diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action
BHM4-CT98-3936. Leukemia. 2007; 21: 201-06.
124. Seiler T, Hiddemann W, Dreyling M. Optimal application of antibodies in the treatment of
follicular lymphoma: current standards and future strategies. Immunotherapy. 2009; 1:
1015-24.
125. Zinzani PL, Gandolfi L, Stefoni V i wsp. Yttrium-90 ibritumomab tiuxetan as a single agent in
patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin
Lymphoma Myeloma Leuk. 2010; 10: 258-61.
126. van Dongen JJ, Seriu T, Panzer-Grümayer ER i wsp. Prognostic value of minimal residual
disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352: 1731-38.
127. Szczepański T, Willemse MJ, Brinkhof B i wsp. Comparative analysis of Ig and TCR gene
rearrangements at diagnosis and at relapse of childhood precursor B-ALL provides improved
strategies for selection of stable PCR targets for monitoring of minimal residual disease,
Blood. 2002; 99: 2315-23.
128. van Dongen J, Langerak A, Szczepański T, van der Volden V. Molecular Monitoring of
Lymphoma. W: Canellos GP, Lister TA, Youn B. (wyd.) The Lymphomas. Saunders Elsevier.
2006: 89-109.
129. Anderson J, Jenkin R, Wilson J i wsp. Long term follow-up of patients treated with COMP or
LSA2-L2 therapy for childhood non-Hodgkin lymphoma: a report of CCG-551 from the
Childrens Cancer Group. J Clin Oncol.1993; 11: 1024-32.
130. Reiter A, Schrappe M, Tieman M i wsp. Improved treatment results in childhood B-cell
neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster
Group Trial NHL-BFM 90. Blood. 1999; 94: 3294-306.
131. Patte C, Auperin A, Michon J i wsp. The Societe Francaise d’Oncology Pediatrique LMB89
protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial
response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;
97: 3370-79.
132. Williams DM, Hobson R, Imeson J i wsp. Anaplastic large cell lymphoma in childhood:
analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group
chemotherapy regimens. Br J Haematol. 2002; 117: 812-20. Review.
133. Le Deley MC, Rosolen A, Williams DM i wsp. Vinblastine in children and adolescents with
high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.
J Clin Oncol. 2010; 28: 3987-93.
134. Reiter A, Schrappe M, Ludwig W i wsp. Intensive ALL-type therapy without local
radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic
lymphoma: a BFM Group report. Bllod. 2000; 95: 416-21.
135. Link M, Shuster J, Donaldson S i wsp. Treatment of children and young adults with earlystage
non-Hodgin lymphoma. N Eng J Med. 1997; 337: 1259-66.
136. Woessmann W, Seidemann K, Mann G i wsp. The impact of the methotrexate administration
schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a raport
of the BFM Group Study NHL-BFM 95. Blood. 2005; 105: 948-58
137. Rodenburg EM, Maartense E, Posthuma EF. Improved survival for patients with large B-cell
lymphoma after introduction of rituximab. Neth J Med. 2009; 67: 355-58.
138. Fields KK, Zorsky PE, Hiemenz JW i wsp. Ifosfamide, carboplatin, and etoposide: a new
regimen with a broad spectrum of activity. J Clin Oncol. 1994; 12: 544-52.
139. Kobrinsky NL, Sposto R, Shah NR i wsp. Outcomes of treatment of children and adolescents
with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone,
142